New cocktail of four chemo drugs shows promise for tough pancreatic cancer
NCT ID NCT06225999
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of four chemotherapy drugs—irinotecan liposome, oxaliplatin, 5-fluorouracil, and levoleucovorin—in 41 Japanese adults with metastatic pancreatic cancer who had not received prior treatment. The goal was to see how well the drugs shrank tumors and to check safety. Participants received the drugs by IV on days 1 and 15 of each 28-day cycle until the disease worsened or side effects became too severe. The study is complete, and results may help guide future treatment options for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
irinotecan liposome, oxaliplatin, 5-fluorouracil, and levoleucovorin
What this could lead to
If this drug combination works well, it could offer a new first-line treatment option for people with metastatic pancreatic cancer, potentially improving tumor shrinkage and survival.
What could go wrong
This is a small, early-phase study with only 41 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the combination may not prove better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ADENOCARCINOMA OF THE PANCREAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center (007)
Nagoya, 464-8681, Japan
-
Chiba Cancer Center (011)
Chiba, 260-8717, Japan
-
Chiba University Hospital (015)
Chiba, 260-8677, Japan
-
Hokkaido University Hospital (004)
Sapporo, 060-8648, Japan
-
Kanagawa Cancer Center (002)
Kanagawa, 241-8515, Japan
-
Kanazawa University Hospital (008)
Ishikawa, 920-8641, Japan
-
National Cancer Center Hospital (001)
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East (003)
Kashiwa, Chiba, 277-8577, Japan
-
National Hospital Organization Kyushu Cancer Center (005)
Fukuoka, 811-1395, Japan
-
National Hospital Organization Shikoku Cancer Center (013)
Ehime, 791-0280, Japan
-
Osaka International Cancer Institute (009)
Osaka, 541-8567, Japan
-
Saitama Cancer Center (012)
Saitama, 362-0806, Japan
-
The Cancer Institute Hospital of JFCR (006)
Tokyo, 135-8550, Japan
-
Yamaguchi University Hospital (010)
Yamaguchi, 755-8505, Japan